Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
recombinant, expressed in NSO cells, lyophilized powder, suitable for cell culture, >97% (SDS-PAGE). Group: Fluorescence/luminescence spectroscopy.
Thrombopoietin human
recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture, ?98% (SDS-PAGE and HPLC). Group: Fluorescence/luminescence spectroscopy.
2-(3,4-Dimethylphenyl)-2,4-dihydro-5-methyl-3H-pyrazol-3-one-13C4 is an intermediate in the synthesis of Eltrombopag-13C4 (E508002), which is an agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 5mg, 10mg. Molecular Formula: C813C4H14N2O. US Biological Life Sciences.
Worldwide
Avatrombopag
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ( EC 50 =3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AKR-501; E5501; YM477. CAS No. 570406-98-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13463.
Avatrombopag
Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 is an orally-active TPO receptor agonist that may be useful in the treatment of patients with thrombocytopenia. Synonyms: AKR-501; AKR 501; AKR501; YM477; YM-477; YM 477; E5501; AS 1670542; AS1670542; AS-1670542. Grades: 98%. CAS No. 570406-98-3. Molecular formula: C29H34Cl2N6O3S2. Mole weight: 649.65.
Avatrombopag hydrochloride
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ( EC 50 =3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride. CAS No. 570403-17-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13463B.
Avatrombopag maleate
Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 is an orally-active TPO receptor agonist that may be useful in the treatment of patients with thrombocytopenia. CAS No. 677007-74-8. Molecular formula: C33H38Cl2N6O7S2. Mole weight: 765.7.
Avatrombopag maleate
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ( EC 50 =3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AKR-501 maleate; E5501 maleate; YM477 maleate. CAS No. 677007-74-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13463A.
Eltrombopag
An agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia. Group: Biochemicals. Alternative Names: 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; SB 497115. Grades: Highly Purified. CAS No. 496775-61-2. Pack Sizes: 10mg. US Biological Life Sciences.
Worldwide
Eltrombopag
Eltrombopag is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR). Uses: Nonpeptide thrombopoietin receptor agonist. Synonyms: SB-497115-GR, SB497115. Grades: >98%. CAS No. 496775-61-2. Molecular formula: C25H22N4O4. Mole weight: 442.47.
Eltrombopag
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SB-497115. CAS No. 496775-61-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15306.
Eltrombopag
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Eltrombopag;3-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid;(1,1-Biphenyl)-3-carboxylic acid, 3-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2-hydroxy-;Eltrombopag [inn];Promacta;Sb497115;Sb-497115;Unii-S56D65xj9g. Product Category: Inhibitors. Appearance: Solid. CAS No. 496775-61-2. Molecular formula: C25H22N4O4. Mole weight: 442.47. Purity: 0.9973. Canonical SMILES: O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O. Density: 1.33. Product ID: ACM496775612. Alfa Chemistry ISO 9001:2015 Certified.
Eltrombopag-13C4
Eltrombopag- 13 C 4 (SB-497115- 13 C 4 ) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus ( Staphylococcus aureus ) and can induce apoptosis ( apoptosis ) in liver cancer cells [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Isotope-labeled compounds. Alternative Names: SB-497115- 13 C4. CAS No. 1217230-31-3. Pack Sizes: 1 mg. Product ID: HY-15306S.
Eltrombopag Olamine
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Eltrombopag diethanolamine salt; SB-497115GR. CAS No. 496775-62-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15306A.
Hetrombopag
Hetrombopag is an orally active human thrombopoietin receptor agonist. Hetrombopag protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells. Hetrombopag specifically stimulated proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways. Notably, hetrombopag effectively up-regulated G1 -phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalized progression of the cell cycle, and prevented apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Uses: Designed for use in research and industrial production. Additional or Alternative Names: SHR8735; SHR 8735; SHR-8735; Hetrombopag. Product Category: Agonists. Appearance: Solid powder. CAS No. 1257792-41-8. Molecular formula: C25H22N4O5. Mole weight: 458.47. Purity: >98%. IUPACName: (E)-5-(2-hydroxy-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)phenyl)furan-2-carboxylic acid. Canonical SMILES: O=C(C1=CC=C(C2=CC=CC(N/N=C3C(N(C4=CC=C5CCCCC5=C4)N=C/3C)=O)=C2O)O1)O. Product ID: ACM1257792418. Alfa Chemistry ISO 9001:2015 Certified.
LGD-4665
LGD-4665, an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies. Research demonstrated that LGD-4665 was well-tolerated with an excellent safety profile. Multiple phase-II studies in thrombocytopenic patients due to ITP, Hep-C and MDS with daily and weekly dosing regimens, as well as additional Phase-I pharmacology studies in healthy volunteers are underway. Synonyms: LGD-4665; LGD 4665; LGD4665. CAS No. 1192571-53-1.
Lusutrombopag
Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist. It acts selectively on the human TPO receptor and activates signal transduction pathways and thereby increases platelet levels. It was developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. It has been listed. Uses: Lusutrombopag was used for chronic liver disease (cld) patients with thrombocytopenia prior to elective invasive surgery. Synonyms: S-888711; S 888711; S888711; (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid. Grades: >98%. CAS No. 1110766-97-6. Molecular formula: C29H32Cl2N2O5S. Mole weight: 591.54.
Lusutrombopag
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease. Uses: Scientific research. Group: Signaling pathways. Alternative Names: S-888711. CAS No. 1110766-97-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19883.
Romiplostim
Romiplostim is a fusion protein analogue of TPO (thrombopoietin protein) Fc peptide, and is a peptide-body molecule. Romiplostim increases platelet production by activating the thrombopoietin receptor TPO receptor. The peptidosome molecule has two identical single-stranded subunits, each consisting of 269 amino acid residues [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 2626841-92-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990685.
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.